Overview
Pioglitazone is a synthetic thiazolidinedione derivative developed by Takeda Pharmaceuticals and approved by the FDA in 1999. As a selective agonist of PPARγ, it modulates gene transcription to enhance insulin sensitivity in adipose tissue, skeletal muscle, and the liver. The drug significantly reduces HbA1c levels by 0.5-1.5% when used as monotherapy, with greater efficacy in combination with metformin or sulfonylureas. Unlike earlier thiazolidinediones (e.g., troglitazone), pioglitazone demonstrates a more favorable hepatic safety profile but requires careful cardiovascular risk assessment.
Physical and Chemical Properties
Pioglitazone's crystalline structure features a thiazolidine-2,4-dione core connected to a pyridine ring via a linker chain, contributing to its receptor binding specificity. The compound shows stability under normal storage conditions but degrades upon prolonged exposure to UV light or high humidity. With a pKa of 6.8, pioglitazone exhibits pH-dependent solubility—higher solubility in acidic media (pH<5) compared to neutral conditions. This property influences its formulation strategies, with most commercial products using immediate-release tablets containing the hydrochloride salt form.
Main Applications
The primary indication for pioglitazone is improving glycemic control in adults with type 2 diabetes, either as monotherapy or combined with other antidiabetic agents. Clinical studies demonstrate particular efficacy in patients with significant insulin resistance. Emerging research explores off-label applications including polycystic ovary syndrome (PCOS) treatment and non-alcoholic steatohepatitis (NASH) management, where its PPARγ-mediated effects may reduce hepatic inflammation and fibrosis. However, these uses require further validation through large-scale clinical trials.
Safety and Storage
Pioglitazone requires careful risk-benefit assessment due to potential adverse effects including weight gain (2-4 kg average), edema (4-6% incidence), and increased fracture risk in postmenopausal women. The FDA issued a black box warning in 2007 regarding heart failure exacerbation. Proper storage involves maintaining the API or finished product in original packaging at controlled room temperature (15-25°C), with desiccants to prevent moisture absorption. Stability studies indicate a typical shelf life of 36 months when stored under recommended conditions.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing pioglitazone API should prioritize suppliers with WHO-GMP or EDQM certification. Key quality parameters include HPLC purity ≥99.5%, residual solvent levels per ICH guidelines, and absence of genotoxic impurities. Bulk procurement contracts should specify: 1) Batch-to-batch consistency requirements, 2) Full analytical documentation including method validation reports, 3) Regulatory support for dossier preparation, and 4) Supply chain transparency from raw materials to finished API. Consider dual-sourcing strategies to mitigate supply chain risks.
Related Manufacturers
- 主营：二苯胺、基嘧啶、甲苯氟、匹格列酮烯、脱乙基、咯喹酮、嘧菌酯、溴苯基、氟磺隆、特戊醛、基哌嗪、氟苯基、碲化钠、酸性红、噻虫啉、双吡啶、三甘醇、异氯磷、茚草酮、吡啶醛、吡啶醇、二羧酸、三硫代碳酸钠、磷酸铁、24滴、聚酯多元醇